Subtopic Deep Dive

Drug-Drug Interactions via Cytochrome Induction Inhibition
Research Guide

What is Drug-Drug Interactions via Cytochrome Induction Inhibition?

Drug-drug interactions via cytochrome induction inhibition involve perpetrators like rifampin (inducers) or ketoconazole (inhibitors) altering CYP450 enzyme activity, changing victim drug exposure and clinical outcomes.

This subtopic focuses on P450-mediated DDIs quantified by inhibition constants (Ki), induction ratios, and PBPK models (Jones and Rowland-Yeo, 2013; 554 citations). Human CYP enzymes metabolize 80% of drugs, with inhibition and induction mechanisms detailed in updates (Hakkola et al., 2020; 353 citations). Over 50 PBPK models verify DDI predictions (Sager et al., 2015; 486 citations).

Curated Papers

Key Challenges

Why It Matters

DDI knowledge prevents adverse events in polypharmacy, as CYP2D6 inhibition phenoconverts extensive metabolizers to poor metabolizers, reducing codeine efficacy (Crews et al., 2011; 366 citations). PBPK modeling supports regulatory dose adjustments, qualifying models for submissions (Shebley et al., 2018; 348 citations). Herbal compounds like eleutherosides inhibit CYP activity, risking interactions (Guo et al., 2014; 288 citations).

Key Research Challenges

Quantifying Induction Magnitude

Induction ratios vary by CYP isoform and time-dependence, complicating predictions (Hakkola et al., 2020). PBPK models require enzyme turnover data often unavailable in humans (Jones and Rowland-Yeo, 2013). Clinical translation remains inconsistent across populations.

Phenoconversion in Polypharmacy

Inhibitors convert genotypic EMs to phenotypic PMs, mimicking genetic poor metabolizers (Shah and Smith, 2014; 255 citations). Multiple co-medications amplify effects, challenging personalized dosing (Crews et al., 2011).

PBPK Model Verification

Systematic reviews show variable model performance in DDI simulations (Sager et al., 2015; 486 citations). Regulatory qualification demands robust verification procedures (Shebley et al., 2018).

Essential Papers

Cytochrome P450 Enzymes and Drug Metabolism in Humans

Mingzhe Zhao, Jingsong Ma, Mo Li et al. · 2021 · International Journal of Molecular Sciences · 850 citations

Human cytochrome P450 (CYP) enzymes, as membrane-bound hemoproteins, play important roles in the detoxification of drugs, cellular metabolism, and homeostasis. In humans, almost 80% of oxidative me...

Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

HM Jones, K Rowland‐Yeo · 2013 · CPT Pharmacometrics & Systems Pharmacology · 554 citations

The aim of this tutorial is to introduce the concept of physiologically based pharmacokinetic (PBPK) modeling to individuals in the pharmaceutical industry who may be relatively new to this area an...

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification

Jennifer E. Sager, Jingjing Yu, Isabelle Ragueneau‐Majlessi et al. · 2015 · Drug Metabolism and Disposition · 486 citations

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger et al. · 2011 · Clinical Pharmacology & Therapeutics · 366 citations

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorph...

Inhibition and induction of CYP enzymes in humans: an update

Jukka Hakkola, Janne Hukkanen, Miia Turpeinen et al. · 2020 · Archives of Toxicology · 353 citations

Abstract The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic com...

Current trends in drug metabolism and pharmacokinetics

Yuhua Li, Qiang Meng, Mengbi Yang et al. · 2019 · Acta Pharmaceutica Sinica B · 351 citations

Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision...

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Mohamad Shebley, Punam Sandhu, Arian Emami Riedmaier et al. · 2018 · Clinical Pharmacology & Therapeutics · 348 citations

This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory submission based on the collective ex...

Reading Guide

Foundational Papers

Start with Jones and Rowland-Yeo (2013; 554 citations) for PBPK basics in DDI; Crews et al. (2011; 366 citations) for CYP2D6 clinical guidelines; Shah and Smith (2014; 255 citations) for phenoconversion concepts.

Recent Advances

Hakkola et al. (2020; 353 citations) updates CYP inhibition/induction; Shebley et al. (2018; 348 citations) details PBPK regulatory qualification; Zhao et al. (2021; 850 citations) overviews human CYP enzymes.

Core Methods

PBPK simulation (Simcyp/GastroPlus); in vitro Ki/IC50 from microsomes/recombinant CYPs; clinical AUC ratios from cocktail studies; nuclear receptor assays for induction.

How PapersFlow Helps You Research Drug-Drug Interactions via Cytochrome Induction Inhibition

Discover & Search

Research Agent uses searchPapers and exaSearch to find PBPK DDI literature, then citationGraph on Zhao et al. (2021; 850 citations) reveals 200+ connected papers on CYP metabolism. findSimilarPapers expands to induction-specific models from Hakkola et al. (2020).

Analyze & Verify

Analysis Agent applies readPaperContent to extract Ki values from Guo et al. (2014), verifies DDI predictions via verifyResponse (CoVe), and runs PythonAnalysis for statistical comparison of induction ratios using pandas. GRADE grading scores evidence strength for regulatory models (Shebley et al., 2018).

Synthesize & Write

Synthesis Agent detects gaps in phenoconversion modeling (Shah and Smith, 2014), flags contradictions in CYP2D6 guidelines (Crews et al., 2011). Writing Agent uses latexEditText, latexSyncCitations, and latexCompile for PBPK workflow diagrams via exportMermaid.

Use Cases

"Extract inhibition constants from eleutheroside CYP studies and plot IC50 curves"

Research Agent → searchPapers('eleutheroside CYP inhibition') → Analysis Agent → readPaperContent(Guo et al. 2014) → runPythonAnalysis(pandas/matplotlib IC50 fitting) → matplotlib plot of dose-response curves.

"Model ketoconazole-rifampin DDI on midazolam using PBPK parameters"

Research Agent → citationGraph(Jones 2013) → Synthesis Agent → gap detection → Writing Agent → latexEditText(PBPK equations) → latexSyncCitations → latexCompile(full model LaTeX report).

"Find GitHub repos with open-source PBPK DDI simulators"

Research Agent → searchPapers('PBPK DDI modeling code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(Simcyp-like Python models) → exportCsv(parameter tables).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ PBPK DDI papers: searchPapers → citationGraph → GRADE all abstracts → structured report on induction verification. DeepScan applies 7-step analysis to Hakkola et al. (2020): readPaperContent → verifyResponse → runPythonAnalysis(enzyme kinetics). Theorizer generates hypotheses on herbal DDI mechanisms from Guo et al. (2014) + Zhao et al. (2021).

Try Doxa for Drug-Drug Interactions via Cytochrome Induction Inhibition Research

Frequently Asked Questions

What defines cytochrome induction inhibition in DDIs?

Inducers like rifampin upregulate CYP expression via nuclear receptors; inhibitors like ketoconazole competitively block active sites, altering victim AUC by 2- to 100-fold (Hakkola et al., 2020).

What are key methods for DDI prediction?

PBPK modeling integrates Ki, induction ratios, and victim fu,in; static models use R1/I values (Jones and Rowland-Yeo, 2013; Sager et al., 2015).

What are seminal papers?

Zhao et al. (2021; 850 citations) reviews CYP metabolism; Crews et al. (2011; 366 citations) provides CPIC CYP2D6 guidelines; Hakkola et al. (2020; 353 citations) updates inhibition/induction.

What open problems exist?

Phenoconversion quantification in polypharmacy (Shah and Smith, 2014); time-dependent inhibition in PBPK (Sager et al., 2015); herbal perpetrator validation (Guo et al., 2014).